Skip to main content
HR 1046 116th Congress House Health Competition and antitrust Drug safety, medical device, and laboratory regulation Health care costs and insurance Inflation and prices Licensing and registrations Manufacturing Medicare Prescription drugs Product safety and quality Public contracts and procurement

Medicare Negotiation and Competitive Licensing Act of 2019

Introduced: February 7, 2019 Introduced by: Doggett, Lloyd Democratic · Texas See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Sep 25, 2019
Subcommittee Hearings Held.
Feb 8, 2019
Referred to the Subcommittee on Health.
Feb 7, 2019
Referred to the Subcommittee on Health.
Feb 7, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Feb 7, 2019
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Medicare Negotiation and Competitive Licensing Act of 2019

This bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. (Current law prohibits the CMS from doing so.)

The CMS must take certain factors into account during negotiations, including the clinical- and cost-effectiveness of the drug, the financial burden on patients, and unmet patient needs. If the CMS is unable to negotiate the price of a drug, such drug is subject to competitive licensing in order to further its sale under Medicare, notwithstanding existing government-granted exclusivities.

Additionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).

What's happening now September 25, 2019

Subcommittee Hearings Held.

 Related & companion bills 1
  • S 377 Related bill Medicare Negotiation and Competitive Licensing Act of 2019
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
 Cosponsors 82
All 82 Democratic 74
D
Jeffries, Hakeem S.
New York · Sep 10, 2019
Lawrence, Brenda
· Jun 19, 2019
 D
Pappas, Chris
New Hampshire · May 23, 2019
 D
Carson, André
Indiana · May 22, 2019
 D
Beyer, Donald S.
Virginia · Mar 27, 2019
Fudge, Marcia
· Mar 25, 2019
PRICE, DAVID
· Mar 8, 2019
 D
Scanlon, Mary Gay
Pennsylvania · Mar 5, 2019
 D
Wilson, Frederica S.
Florida · Feb 27, 2019
 D
Clarke, Yvette D.
New York · Feb 25, 2019
Gabbard, Tulsi
· Feb 25, 2019
 D
Huffman, Jared
California · Feb 25, 2019
 D
Lieu, Ted
California · Feb 25, 2019
Delgado, Antonio
· Feb 14, 2019
 D
Soto, Darren
Florida · Feb 14, 2019
 D
García, Jesús G. "Chuy"
Illinois · Feb 11, 2019
 D
Morelle, Joseph D.
New York · Feb 11, 2019
 D
Adams, Alma S.
North Carolina · Feb 7, 2019
 D
Beatty, Joyce
Ohio · Feb 7, 2019
 D
Bonamici, Suzanne
Oregon · Feb 7, 2019
 D
Case, Ed
Hawaii · Feb 7, 2019
 D
Casten, Sean
Illinois · Feb 7, 2019
 D
Castor, Kathy
Florida · Feb 7, 2019
 D
Castro, Joaquin
Texas · Feb 7, 2019
 D
Chu, Judy
California · Feb 7, 2019
 D
Cisneros, Gilbert Ray
California · Feb 7, 2019
 D
Cleaver, Emanuel
Missouri · Feb 7, 2019
 D
Cohen, Steve
Tennessee · Feb 7, 2019
 D
Courtney, Joe
Connecticut · Feb 7, 2019
Crist, Charlie
· Feb 7, 2019
 D
Crow, Jason
Colorado · Feb 7, 2019
 D
Davis, Danny K.
Illinois · Feb 7, 2019
 D
DeLauro, Rosa L.
Connecticut · Feb 7, 2019
 D
DeSaulnier, Mark
California · Feb 7, 2019
 D
Dingell, Debbie
Michigan · Feb 7, 2019
 D
Escobar, Veronica
Texas · Feb 7, 2019
 D
Espaillat, Adriano
New York · Feb 7, 2019
 D
Evans, Dwight
Pennsylvania · Feb 7, 2019
 D
Frankel, Lois
Florida · Feb 7, 2019
 D
Gallego, Ruben
Arizona · Feb 7, 2019
 D
Garamendi, John
California · Feb 7, 2019
 D
Golden, Jared F.
Maine · Feb 7, 2019
 D
Gonzalez, Vicente
Texas · Feb 7, 2019
 D
Green, Al
Texas · Feb 7, 2019
 D
Harder, Josh
California · Feb 7, 2019
 D
Jayapal, Pramila
Washington · Feb 7, 2019
 D
Kaptur, Marcy
Ohio · Feb 7, 2019
 D
Khanna, Ro
California · Feb 7, 2019
 D
Kim, Andy
New Jersey · Feb 7, 2019
 D
Krishnamoorthi, Raja
Illinois · Feb 7, 2019
Page 1 of 2 Next
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 1046: Medicare Negotiation and Competitive Licensing Act of 2019. 116th Congress. Open America. https://openamerica.io/bill/116-HR-1046/
MLA
"H.R. 1046: Medicare Negotiation and Competitive Licensing Act of 2019." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-1046/.
Bluebook (legal)
H.R. 1046, 116th Cong. (2026), https://openamerica.io/bill/116-HR-1046/.
Markdown link
[H.R. 1046: Medicare Negotiation and Competitive Licensing Act of 2019](https://openamerica.io/bill/116-HR-1046/)
Report a problem